Read by QxMD icon Read

Clinical Breast Cancer

Won Kyung Cho, Won Park, Doo Ho Choi, Yong Bae Kim, Jin Ho Kim, Su Ssan Kim, Kyubo Kim, Jin Hee Kim, Sung Ja Ahn, Sun Young Lee, Jeongshim Lee, Sang-Won Kim, Jeanny Kwon, Ki Jung Ahn
BACKGROUND: Given the lack of established indications for elective nodal irradiation (ENI) in ypN0 patients after neoadjuvant chemotherapy (NAC) and breast-conserving surgery (BCS), we set out to investigate the role of ENI in ypN0 patients according to subtype and pathologic complete remission (pCR) status. PATIENTS AND METHODS: We analyzed 261 patients who received NAC followed by BCS and adjuvant radiotherapy in 13 institutions of the Korean Radiation Oncology Group from 2005 to 2011...
August 28, 2018: Clinical Breast Cancer
Naoki Hayashi, Hiroko Tsunoda, Maki Namura, Tomohiro Ochi, Koyu Suzuki, Hideko Yamauchi, Seigo Nakamura
BACKGROUND: Magnetic resonance imaging (MRI) or ultrasonography (US) alone is limited in the ability to predict the pathologic complete response (pCR) accurately after neoadjuvant chemotherapy (NAC). The aim of the present study was to predict the pCR using MRI combined with second-look US in primary breast cancer patients. MATERIALS AND METHODS: A total of 1274 consecutive primary breast cancer patients who were examined by MRI and second-look US before and after NAC and had undergone breast-conserving surgery from 2004 to 2014 were included...
August 24, 2018: Clinical Breast Cancer
Barbara Pistilli, Chafika Mazouni, Anna Zingarello, Matthieu Faron, Mahasti Saghatchian, Michael Grynberg, Marc Spielmann, Paul Kerbrat, Henri Roché, Veronique Lorgis, Thomas Bachelot, Mario Campone, Christelle Levy, Anthony Gonçalves, Anne Lesur, Corinne Veyret, Laurence Vanlemmens, Jerome Lemonnier, Suzette Delaloge
BACKGROUND: The likelihood of menses recovery varies greatly in premenopausal patients receiving adjuvant chemotherapy for breast cancer. Quantifying this probability for each patient could better inform the chemotherapy discussion and individualize fertility counseling. We performed a pooled analysis of the PACS04 and PACS05 adjuvant randomized trials to develop a nomogram to estimate the probability of menses recovery at 3, 6, and 18 months after the end of adjuvant chemotherapy. PATIENTS AND METHODS: Women who were premenopausal and aged ≤ 50 years at randomization in the PACS04 and PACS05 trials were included in the present analysis...
August 23, 2018: Clinical Breast Cancer
Carlos Adrián Alarcón Rojas, María Teresa Alvarez-Bañuelos, Jaime Morales-Romero, Héctor Suárez-Díaz, Juan Carlos Hernández-Fonseca, Guillermo Contreras-Alarcón
INTRODUCTION: We assessed the association between overweight, obesity, and morbid obesity with the incidence of the most aggressive breast cancer subtypes in women. METHODS AND MATERIALS: A cross-sectional study was performed. We conducted a record review to identify the following aspects: body mass index, sociodemographic features, tumor characteristics, and reproductive and molecular aspects. Descriptive statistics and univariate analysis were performed to identify the association between the molecular subtypes and the study variables...
August 22, 2018: Clinical Breast Cancer
Karuvaje Thriveni, Anisha Raju, Rekha V Kumar, Swamyvelu Krishnamurthy, Ramesh Chaluvarayaswamy
BACKGROUND: Homeostasis of telomere in breast cancer might be altered as a result of cumulative effects of various factors causing genomic instability and affecting prognosis. This study aimed to compare the relative telomere length (RTL) and hTERT mRNA expression in the tissue of patients with breast cancer along with the clinicopathologic parameters. PATIENTS AND METHODS: Frozen tumor tissues and adjacent normal breast tissue from 98 patients with invasive ductal breast cancer were used for the analysis...
August 22, 2018: Clinical Breast Cancer
Josef Hammer, Hans Geinitz, Carsten Nieder, Christine Track, Howard D Thames, Dietmar H Seewald, Andreas L Petzer, Ruth Helfgott, Kurt J Spiegl, Dietmar Heck, Elisabeth Bräutigam
BACKGROUND: The purpose of this study was to analyze risk factors for ipsilateral in-breast relapse and inferior disease-free survival (DFS) after standard adjuvant whole-breast radiotherapy (± boost and systemic treatment) as part of a multimodal breast-conserving approach. PATIENTS AND METHODS: Decision trees were built through recursive partitioning analysis (RPA). The median follow-up for all 2161 patients was 114 months (9.5 years). RESULTS: Local relapse in the treated breast was uncommon (actuarial rates after 5 and 10 years were 2...
August 22, 2018: Clinical Breast Cancer
Yonggeng Goh, Ghayathri Balasundaram, Mohesh Moothanchery, Amalina Attia, Xiuting Li, Hann Qian Lim, Neal Burton, Yi Qiu, Thomas Choudary Putti, Ching Wan Chan, Philip Iau, Siau Wei Tang, Celene Wei Qi Ng, Felicity Jane Pool, Premilla Pillay, Wynne Chua, Eide Sterling, Swee Tian Quek, Malini Olivo
No abstract text is available yet for this article.
August 16, 2018: Clinical Breast Cancer
Sylvère Guillemois, Anne Patsouris, Guillaume Peyraga, Kévin Chassain, Yannick Le Corre, Mario Campone, Paule Augereau
No abstract text is available yet for this article.
August 14, 2018: Clinical Breast Cancer
Norbert Marschner, Christoph Salat, Ulrike Söling, Richard Hansen, Sina Grebhardt, Johanna Harde, Arnd Nusch, Karin Potthoff
BACKGROUND: One of the most effective chemotherapies for metastatic breast cancer (MBC) is nab-paclitaxel (nab-P), which is approved for treatment of MBC after failure of first-line therapy and when anthracyclines are not indicated. Randomized clinical trials have shown high efficacy and acceptable toxicity. Real-world data of nab-P in MBC, however, are still limited. PATIENTS AND METHODS: The prospective multicenter noninterventional study NABUCCO collected data on the routine treatment of patients with MBC receiving nab-P in 128 sites across Germany...
August 9, 2018: Clinical Breast Cancer
Juanjuan He, Yuanting Gu, Shaojin Zhang
BACKGROUND: The association between vitamin A intake and breast cancer survival has been inconsistent. We conducted a systemic review and meta-analysis to summarize the results on the association between dietary or supplement vitamin A and its derivatives and breast cancer-specific survival and overall survival (OS). MATERIALS AND METHODS: A comprehensive search of PubMed and EMBASE was performed from inception to January 31, 2018. The summary hazard ratios and 95% confidence intervals were estimated using a random effects model...
August 4, 2018: Clinical Breast Cancer
Guanghui Ji, Chenyang Zhang, Shan Guan, Xiangying Yao
No abstract text is available yet for this article.
August 4, 2018: Clinical Breast Cancer
Hope S Rugo, Henri Roche, Eva Thomas, Hyun C Chung, Guillermo L Lerzo, Igor Vasyutin, Amit Patel, Linda Vahdat
INTRODUCTION: The purpose of this study was to evaluate the safety and efficacy of ixabepilone plus capecitabine in patients with metastatic or locally advanced triple-negative breast cancer (TNBC). PATIENTS AND METHODS: We conducted a pooled analysis of patients with TNBC enrolled in 2 phase III trials (NCT00080301 and NCT00082433), pretreated or resistant to an anthracycline and a taxane. In each study, patients were randomized to receive ixabepilone 40 mg/m2 (3-hour intravenous infusion, day 1), plus oral capecitabine 1000 mg/m2 twice daily (days 1-14), or capecitabine alone 1250 mg/m2 twice daily (days 1-14), every 3 weeks...
August 4, 2018: Clinical Breast Cancer
Zuzana Sporikova, Vladimira Koudelakova, Radek Trojanec, Marian Hajduch
Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancer cases and is characterized by the absence of estrogen, progesterone, and human epidermal growth factor 2 receptors. Though TNBC is a highly heterogenic and aggressive disease, TNBC patients have better response to neoadjuvant therapy compared to other breast cancer subtypes. Nevertheless, patients with residual disease have a very poor prognosis, with higher probability of relapse and lower overall survival in the first years after diagnosis...
August 4, 2018: Clinical Breast Cancer
Vered Stearns, Adam M Brufsky, Shailendra Verma, Matthew J Cotter, Dongrui R Lu, Florence Dequen, Anil Abraham Joy
PURPOSE: Palbociclib is a cyclin-dependent kinase (CDK) 4 and 6 inhibitor that was conditionally approved in the United States (February 2015) and Canada (March 2016) with letrozole as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. A palbociclib expanded-access program (EAP) was initiated as an interim measure to provide drug access before commercial availability of drug...
July 30, 2018: Clinical Breast Cancer
Lawrence Paszat, Rinku Sutradhar, Limei Zhou, Sharon Nofech-Mozes, Eileen Rakovitch
INTRODUCTION: Individual prediction of local recurrence (LR) risk after breast-conserving surgery (BCS) for ductal carcinoma-in-situ (DCIS) is needed to identify women at low risk, for whom radiotherapy may be omitted. PATIENTS AND METHODS: Three predictive models of LR-clinicopathologic factors (CPF) alone; CPF + estrogen receptor (ER) + human epidermal growth factor receptor 2 (HER2); and CPF + DCIS score (DS)-were developed among 1102 cases of DCIS in patients with complete covariate and outcome data...
July 29, 2018: Clinical Breast Cancer
Ola S Ali, Marwa I Shabayek, Mae M Seleem, Heba G Abdellateif, Dalia O Makhlouf
INTRODUCTION: Breast cancer (BC) is the most common malignancy among women; supporting the need for identification of novel prognostic biomarkers, circulating microRNAs (miRNAs) could serve as such in various cancers. The aim of this study was to explore the association between miRNAs 182 and 375 with BC stages and its receptors, based on their expression using real time PCR. MATERIALS AND METHODS: Detailed medical history was taken and blood samples were withdrawn from 80 female subjects divided over the studied groups...
July 29, 2018: Clinical Breast Cancer
Jacques Raphael, Alex Kiss, Sharon Nofech-Mozes, Maureen Trudeau
PURPOSE: To compare tumor response rates and survival outcomes between single and double hormone receptor (HR)-positive breast cancer (BC) patients treated with neoadjuvant chemotherapy. PATIENTS AND METHODS: A retrospective review was conducted using the Sunnybrook Biomatrix database to identify eligible patients. A multivariable logistic regression analysis was performed to assess the association between HR status (single/double HR+ ) and pathologic complete response (pCR) rates...
July 29, 2018: Clinical Breast Cancer
Gopal R Vijayaraghavan, Srinivasan Vedantham, Gabriela Santos-Nunez, Rebecca Hultman
BACKGROUND: We systematically analyzed the extent of disease in unifocal invasive lobular carcinoma (ILC) using ultrasonography, with the histopathologic findings as the reference standard. PATIENTS AND METHODS: In the present single-institution retrospective study, 128 cases of ILC were identified during a 5-year period. After exclusions, the analyzed cohort included 66 cases. Ultrasound measurements of the tumor extent along 3 axes were obtained. The tumor size was determined as the largest extent among the 3 axes and the tumor volume by ellipsoidal approximation...
July 27, 2018: Clinical Breast Cancer
Marta D'Alonzo, Eleonora Piva, Silvia Pecchio, Viola Liberale, Paola Modaffari, Riccardo Ponzone, Nicoletta Biglia
INTRODUCTION: BRCA 1 and 2 mutation carriers are invited to follow intensive clinical and instrumental surveillance programs or are offered prophylactic breast and ovarian surgery. These recommendations impact many aspects of their life. This study aims to evaluate the satisfaction with surveillance and prophylactic surgery and the impact of these procedures on the quality of life. PATIENTS AND METHODS: An anonymous questionnaire was administered to 174 BRCA1-2 mutation carriers...
July 26, 2018: Clinical Breast Cancer
Xuelian Chen, Ying Fan, Binghe Xu
INTRODUCTION: Patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+ /HER2- ) breast cancer have a constant risk of relapse over time. Nearly one-half of the recurrences occur more than 5 years after diagnosis, described as late recurrence, but little is known about late recurrence. PATIENTS AND METHODS: We reviewed the clinical data of 1941 patients with HR+ /HER2- breast cancer who had operations in the Cancer Institute and Hospital, Chinese Academy of Medical Sciences, during 2003 to 2009, and found 390 relapsed cases...
July 24, 2018: Clinical Breast Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"